Jw Pharmac (001060) - Total Assets
Based on the latest financial reports, Jw Pharmac (001060) holds total assets worth ₩605.27 Billion KRW (≈ $410.18 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 001060 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Jw Pharmac - Total Assets Trend (2000–2025)
This chart illustrates how Jw Pharmac's total assets have evolved over time, based on quarterly financial data. Explore Jw Pharmac long-term investment allocation to see how much of total assets are deployed in long-term investments.
Jw Pharmac - Asset Composition Analysis
Current Asset Composition (December 2025)
Jw Pharmac's total assets of ₩605.27 Billion consist of 49.0% current assets and 51.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.5% |
| Accounts Receivable | ₩114.57 Billion | 18.9% |
| Inventory | ₩109.90 Billion | 18.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩64.46 Billion | 10.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Jw Pharmac's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jw Pharmac market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jw Pharmac's current assets represent 49.0% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2025, down from 15.1% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 18.9% of total assets.
Jw Pharmac Competitors by Total Assets
Key competitors of Jw Pharmac based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Jw Pharmac - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.42 | 1.47 | 1.38 |
| Quick Ratio | 0.89 | 0.93 | 0.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩87.35 Billion | ₩97.80 Billion | ₩94.41 Billion |
Jw Pharmac - Advanced Valuation Insights
This section examines the relationship between Jw Pharmac's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.92 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.1% |
| Total Assets | ₩605.27 Billion |
| Market Capitalization | $416.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jw Pharmac's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jw Pharmac's assets grew by 0.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jw Pharmac (2000–2025)
The table below shows the annual total assets of Jw Pharmac from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩605.27 Billion ≈ $410.18 Million |
+0.11% |
| 2024-12-31 | ₩604.60 Billion ≈ $409.73 Million |
-6.27% |
| 2023-12-31 | ₩645.04 Billion ≈ $437.13 Million |
+2.72% |
| 2022-12-31 | ₩627.97 Billion ≈ $425.57 Million |
-0.80% |
| 2021-12-31 | ₩633.05 Billion ≈ $429.01 Million |
+15.29% |
| 2020-12-31 | ₩549.09 Billion ≈ $372.11 Million |
-4.21% |
| 2019-12-31 | ₩573.21 Billion ≈ $388.45 Million |
-3.47% |
| 2018-12-31 | ₩593.79 Billion ≈ $402.40 Million |
-5.88% |
| 2017-12-31 | ₩630.87 Billion ≈ $427.53 Million |
-3.10% |
| 2016-12-31 | ₩651.08 Billion ≈ $441.23 Million |
+6.13% |
| 2015-12-31 | ₩613.48 Billion ≈ $415.75 Million |
+3.26% |
| 2014-12-31 | ₩594.12 Billion ≈ $402.63 Million |
+0.81% |
| 2013-12-31 | ₩589.37 Billion ≈ $399.41 Million |
-2.28% |
| 2012-12-31 | ₩603.15 Billion ≈ $408.74 Million |
-9.59% |
| 2011-12-31 | ₩667.09 Billion ≈ $452.08 Million |
+29.32% |
| 2006-12-31 | ₩515.85 Billion ≈ $349.58 Million |
+7.92% |
| 2005-12-31 | ₩477.97 Billion ≈ $323.91 Million |
+4.46% |
| 2004-12-31 | ₩457.56 Billion ≈ $310.08 Million |
+11.06% |
| 2003-12-31 | ₩412.00 Billion ≈ $279.21 Million |
+6.85% |
| 2002-12-31 | ₩385.60 Billion ≈ $261.32 Million |
+0.08% |
| 2001-12-31 | ₩385.28 Billion ≈ $261.10 Million |
-3.06% |
| 2000-12-31 | ₩397.46 Billion ≈ $269.35 Million |
-- |
About Jw Pharmac
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more